Product Overview
SS-31 (Elamipretide): Targeted Mitochondrial Energy & Cellular Protection
Why SS-31 is of special interest to patients: Mitochondrial decline contributes to fatigue, muscle weakness, and age-related energy loss. By gently restoring mitochondrial function at the source, SS-31 supports sustained vitality, exercise tolerance, and resilience in energy-demanding tissues like heart, muscle, and brain.
Potential Benefits Shown in Early Limited Evaluations Early research (pre-clinical and small human studies) has explored:
- Improved mitochondrial respiration and reduced oxidative stress in aging or diseased cells.
- Better physical performance and cardiac function in animal stress models.
- Promising safety and subtle energy/metabolic improvements in early human mitochondrial disorder trials. Findings are encouraging but from limited evaluations; larger confirmatory studies continue.
- Noted: SS-31 has been stated to be stacked with other peptides. Possibly these stacks may provide for potential enhanced results depending on research indication of interest. These finding are limited and should be researched more fully in human studies for safety and efficacy. Human clinical data remains limited, and it is not FDA-approved for therapeutic use primarily researched or used off-label/investigationally.
SS-31 is a simple tetrapeptide – just 4 amino acids long, with the sequence D-Arg-Dmt-Lys-Phe-NH₂. SS-31 is synthetic mitochondria-targeting peptide designed to mimic and enhance the body’s natural mechanisms for protecting cellular energy factories (mitochondria) during stress or aging.
How it works (Mechanism of Action): SS-31 selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing the electron transport chain, reducing harmful reactive oxygen species, and restoring efficient ATP production—without affecting other cell systems.
Backed by science:
- Pre-clinical studies in isolated mitochondria and animal models of heart failure and neurodegeneration showed SS-31 restores electron transport efficiency, boosts ATP, and protects against oxidative damage.
- Clinical data in patients with primary mitochondrial myopathy confirmed SS-31 is well-tolerated and improves functional measures in early-phase trials.